These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12538044)

  • 1. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant.
    Sanderson SD; Cheruku SR; Padmanilayam MP; Vennerstrom JL; Thiele GM; Palmatier MI; Bevins RA
    Int Immunopharmacol; 2003 Jan; 3(1):137-46. PubMed ID: 12538044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin.
    Tempero RM; Hollingsworth MA; Burdick MD; Finch AM; Taylor SM; Vogen SM; Morgan EL; Sanderson SD
    J Immunol; 1997 Feb; 158(3):1377-82. PubMed ID: 9013982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant.
    Ulrich JT; Cieplak W; Paczkowski NJ; Taylor SM; Sanderson SD
    J Immunol; 2000 May; 164(10):5492-8. PubMed ID: 10799917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
    Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
    Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines.
    Duryee MJ; Bevins RA; Reichel CM; Murray JE; Dong Y; Thiele GM; Sanderson SD
    Vaccine; 2009 May; 27(22):2981-8. PubMed ID: 19428909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing the protective effects of a conformationally constrained nicotine vaccine.
    Moreno AY; Azar MR; Koob GF; Janda KD
    Vaccine; 2012 Oct; 30(47):6665-70. PubMed ID: 22963803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of a multivalent peptide vaccine for nicotine addiction.
    Zeigler DF; Roque R; Clegg CH
    Vaccine; 2019 Mar; 37(12):1584-1590. PubMed ID: 30772068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells.
    Hegde GV; Meyers-Clark E; Joshi SS; Sanderson SD
    Int Immunopharmacol; 2008 Jun; 8(6):819-27. PubMed ID: 18442785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.
    Morgan EL; Morgan BN; Stein EA; Vitrs EL; Thoman ML; Sanderson SD; Phillips JA
    Vaccine; 2009 Dec; 28(2):463-9. PubMed ID: 19836478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations using immunization to attenuate the psychoactive effects of nicotine.
    Carrera MR; Ashley JA; Hoffman TZ; Isomura S; Wirsching P; Koob GF; Janda KD
    Bioorg Med Chem; 2004 Feb; 12(3):563-70. PubMed ID: 14738965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
    Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
    J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.
    Le HT; Fraleigh NL; Lewicky JD; Boudreau J; Dolinar P; Bhardwaj N; Diaz-Mitoma F; Montaut S; Fallahi S; Martel AL
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32178357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier.
    Miller KD; Roque R; Clegg CH
    PLoS One; 2014; 9(12):e114366. PubMed ID: 25494044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates.
    McCluskie MJ; Thorn J; Gervais DP; Stead DR; Zhang N; Benoit M; Cartier J; Kim IJ; Bhattacharya K; Finneman JI; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Dec; 29(2):663-671. PubMed ID: 26404190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats.
    Pentel PR; Malin DH; Ennifar S; Hieda Y; Keyler DE; Lake JR; Milstein JR; Basham LE; Coy RT; Moon JW; Naso R; Fattom A
    Pharmacol Biochem Behav; 2000 Jan; 65(1):191-8. PubMed ID: 10638653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of response-selective agonists of human C5a anaphylatoxin: conformational, biological, and therapeutic considerations.
    Taylor SM; Sherman SA; Kirnarsky L; Sanderson SD
    Curr Med Chem; 2001 May; 8(6):675-84. PubMed ID: 11281848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation.
    Vogen SM; Paczkowski NJ; Kirnarsky L; Short A; Whitmore JB; Sherman SA; Taylor SM; Sanderson SD
    Int Immunopharmacol; 2001 Nov; 1(12):2151-62. PubMed ID: 11710544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
    Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates.
    McCluskie MJ; Thorn J; Mehelic PR; Kolhe P; Bhattacharya K; Finneman JI; Stead DR; Piatchek MB; Zhang N; Chikh G; Cartier J; Evans DM; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Apr; 25(2):518-27. PubMed ID: 25737198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease.
    Landlinger C; Oberleitner L; Gruber P; Noiges B; Yatsyk K; Santic R; Mandler M; Staffler G
    J Neuroinflammation; 2015 Aug; 12():150. PubMed ID: 26275910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.